{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:06Z","timestamp":1793383746089,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociaci\u00f3n Latinoamericana del T\u00f3rax convened to update clinical practice guidelines for interstitial lung disease (ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct a systematic review to evaluate existing ILD literature to determine whether patients with progressive pulmonary fibrosis (PPF) should be treated with the antifibrotic nintedanib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature search was conducted across MEDLINE, EMBASE, and Cochrane databases through December 2020 for studies using nintedanib to treat patients with PPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction<\/jats:title>\n                    <jats:p>Mortality, disease progression, and adverse event data were extracted, and meta-analyses performed when possible. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group approach was used to assess the quality of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Synthesis<\/jats:title>\n                    <jats:p>Two relevant studies were selected. The annual decline in forced vital capacity was less in the nintedanib arm in the overall study population (mean difference [MD], 107 ml\/yr; 95% confidence interval [CI], 65.4 to 148.5 ml\/yr) and in the subgroups with usual interstitial pneumonia (UIP) pattern of pulmonary fibrosis (MD, 128.2 ml\/yr; 95% CI, 70.8 to 185.6 ml\/yr), non-UIP patterns of pulmonary fibrosis (MD, 75.3 ml\/yr; 95% CI, 15.5 to 135.0 ml\/yr), fibrotic connective tissue disease-related ILD (MD, 106.2 ml\/yr; 95% CI, 10.6 to 201.9 ml\/yr), fibrotic idiopathic nonspecific interstitial pneumonia (MD, 141.7 ml\/yr; 95% CI, 46.0 to 237.4 ml\/yr), and fibrotic occupational ILD (MD, 252.8 ml\/yr; 95% CI, 79.2 to 426.5 ml\/yr), but not fibrotic hypersensitivity pneumonitis (MD, 72.9 ml\/yr; 95% CI, \u22128.9 to 154.7 ml\/yr), fibrotic sarcoidosis (MD, \u221220.5 ml\/yr; 95% CI, \u2212337.1 to 296.1 ml\/yr), or unclassified fibrotic ILD (MD, 68.5 ml\/yr; 95% CI, \u221231.3 to 168.4 ml\/yr) when compared with placebo. Gastrointestinal side effects were common. Quality of evidence for the outcomes ranged from very low to moderate GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nintedanib use in patients with PPF is associated with a statistically significant decrease in disease progression but increase in gastrointestinal side effects regardless of the radiographic pattern of pulmonary fibrosis. However, limitations in the available evidence lead to low certainty in these effect estimates and make definitive conclusions about the differential effects by subtype of ILD difficult to determine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary Source of Funding<\/jats:title>\n                    <jats:p>Funded by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociaci\u00f3n Latinoamericana del T\u00f3rax.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202103-343oc","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:35:12Z","timestamp":1651491312000},"page":"1040-1049","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":61,"title":["Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6822","authenticated-orcid":false,"given":"Marya","family":"Ghazipura","sequence":"first","affiliation":[{"name":"ZS Associates, Global Health Economics and Outcomes Research, New York, New York"},{"name":"Divisions of Epidemiology and Biostatistics, Department of Population Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0343-3234","authenticated-orcid":false,"given":"Manoj J.","family":"Mammen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick D.","family":"Herman","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-8407","authenticated-orcid":false,"given":"Stephanie M.","family":"Hon","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Tufts University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-9731","authenticated-orcid":false,"given":"Brittany D.","family":"Bissell","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, College of Medicine, and"},{"name":"Pharmacy Practice and Science Department, College of Pharmacy, University of Kentucky, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-9587","authenticated-orcid":false,"given":"Madalina","family":"Macrea","sequence":"additional","affiliation":[{"name":"Section of Pulmonary and Sleep Medicine, Department of Medicine, Salem Veterans Affairs Medical Center, Salem, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-5080","authenticated-orcid":false,"given":"Fayez","family":"Kheir","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Interventional Pulmonary, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yet H.","family":"Khor","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-3833","authenticated-orcid":false,"given":"Shandra L.","family":"Knight","sequence":"additional","affiliation":[{"name":"Library and Knowledge Sciences, National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-6643","authenticated-orcid":false,"given":"Ganesh","family":"Raghu","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4429-2263","authenticated-orcid":false,"given":"Kevin C.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1995-7828","authenticated-orcid":false,"given":"Tanzib","family":"Hossain","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Grossman School of Medicine, New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2026012203322549100_bib1","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203322549100_bib2","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026012203322549100_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir Res"},{"key":"2026012203322549100_bib4","doi-asserted-by":"crossref","first-page":"180077","DOI":"10.1183\/16000617.0077-2018","article-title":"The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype","volume":"27","author":"Olson","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2026012203322549100_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203322549100_bib6","first-page":"343","article-title":"Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis","volume":"11","author":"Meyer","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2026012203322549100_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026012203322549100_bib8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026012203322549100_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00408-020-00370-1","article-title":"Advances in targeted therapy for progressive fibrosing interstitial lung disease","volume":"198","author":"Gibson","year":"2020","journal-title":"Lung"},{"key":"2026012203322549100_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/17476348.2020.1784730","article-title":"The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease","volume":"14","author":"Sarkar","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"2026012203322549100_bib11","doi-asserted-by":"crossref","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","article-title":"What\u2019s in a name? That which we call IPF, by any other name would act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur Respir J"},{"key":"2026012203322549100_bib12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026012203322549100_bib13","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203322549100_bib14","doi-asserted-by":"crossref","first-page":"e000212","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"2026012203322549100_bib15","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s12325-019-00992-9","article-title":"Management of fibrosing interstitial lung diseases","volume":"36","author":"Maher","year":"2019","journal-title":"Adv Ther"},{"key":"2026012203322549100_bib16","doi-asserted-by":"crossref","first-page":"e000289","DOI":"10.1136\/bmjresp-2018-000289","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial","volume":"5","author":"Maher","year":"2018","journal-title":"BMJ Open Respir Res"},{"key":"2026012203322549100_bib17","doi-asserted-by":"crossref","first-page":"180074","DOI":"10.1183\/16000617.0074-2018","article-title":"Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence","volume":"27","author":"Richeldi","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2026012203322549100_bib18","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203322549100_bib19","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203322549100_bib20","author":"Higgins","year":"2020"},{"key":"2026012203322549100_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026012203322549100_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203322549100_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.resinv.2020.10.005","article-title":"Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: subgroup analysis of the SENSCIS trial","volume":"59","author":"Azuma","year":"2021","journal-title":"Respir Investig"},{"key":"2026012203322549100_bib24","doi-asserted-by":"crossref","first-page":"00152-2020","DOI":"10.1183\/23120541.00152-2020","article-title":"Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study","volume":"6","author":"Tzilas","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012203322549100_bib25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012203322549100_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2026012203322549100_bib27","author":"ClinicalTrials.gov","year":"2019"},{"key":"2026012203322549100_bib28","author":"ClinicalTrials.gov","year":"2021"},{"key":"2026012203322549100_bib29","author":"ClinicalTrials.gov","year":"2020"},{"key":"2026012203322549100_bib30","author":"ClinicalTrials.gov","year":"2017"},{"key":"2026012203322549100_bib31","author":"ClinicalTrials.gov","year":"2020"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/19\/6\/1040\/66331265\/annalsats_19_6_1040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/19\/6\/1040\/66331265\/annalsats_19_6_1040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:35:27Z","timestamp":1769070927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/19\/6\/1040\/8418870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202103-343oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"2021-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}